Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors
about
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cellsDifferent maturation cocktails provide dendritic cells with different chemoattractive properties.Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure.Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cellsCD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancerComparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer modelActivated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of conceptDistinct signatures of the immune responses in low risk versus high risk neuroblastomaA multiscale systems perspective on cancer, immunotherapy, and Interleukin-12A signature of immune function genes associated with recurrence-free survival in breast cancer patients.Synthesis and characterization of intrinsically radiolabeled quantum dots for bimodal detection.Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.Adaptive immune responses associated with breast cancer relapse.Infiltrating CD11b+CD11c+ cells have the potential to mediate inducible nitric oxide synthase-dependent cell death in mammary carcinomas of HER-2/neu transgenic mice.Revisiting cancer immunoediting by understanding cancer immune complexity.Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure?Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response.Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation.
P2860
Q24647546-E1D9A9C4-86AD-48C5-8312-F57787C99E35Q30315866-435A87DE-F2CD-43D8-B120-7C90DD95D915Q33479314-FC16910E-C603-4A1F-A7AC-8A157260D04EQ33587040-F037CABB-D3EB-4924-8F83-50EE2172159FQ34137180-30AF56FB-00FE-4C27-A66F-4DC346EE572AQ34427467-E083AC17-65F6-4A0E-BFAC-80945E4598A6Q34790346-8F2AEDAA-B1D1-49EC-A158-5CC76CE682BCQ34877332-BD99195E-3934-4970-9844-B827483A75D1Q34905454-B18D40A8-C4A7-412C-8CCC-528DE29F1B1CQ35056217-F6E351FF-B239-4ABD-AA7F-F2EC59552FB9Q35091491-14CFA041-FB44-484E-98C1-B3CE9F9D67D7Q35193892-7D0800DB-B391-4110-9CF8-B6ECE6D1ACD8Q35373780-5EDDF818-2C19-4A1C-98E9-987C05EE6A09Q35624686-5D2065CB-E3BD-45A0-9CC5-043FDC16A4ABQ36199789-53AC39A4-4ACF-4520-B0CD-219E1E792D76Q36337243-549A40EB-611C-462D-A8AF-7891680CBB30Q36419244-1E0E284E-956E-4F8F-8CAD-11465E8BB517Q37113513-763A424D-988F-4192-AA19-E1F7F678F0C2Q37170767-74E4D977-ECAC-4A89-96C6-3D141501C893Q37426386-07397112-4692-4D2D-932A-DF92370DAA6BQ38036579-14372994-0328-4BE4-8C50-173B98BFE11CQ39816984-3E5E551F-D61D-439D-847B-1A3E53C6C8BCQ42731574-C76BEE1B-E448-489B-A6AB-8FEA139075A1Q43063200-B3D72F99-5490-4149-AFA1-1522DB3785C9Q48030659-E886127D-0307-4091-AC65-1AC087301E5DQ51035013-5C0BAC2D-D86F-45D9-B0A5-96013EC9256FQ54501638-DD30D278-0464-4DDC-9401-CF138D369FB1
P2860
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors
@en
type
label
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors
@en
prefLabel
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors
@en
P2093
P2860
P1433
P1476
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors
@en
P2093
Andrea Worschech
Francesco M Marincola
Harry D Bear
Keith L Knutson
Maciej Kmieciak
Masoud H Manjili
P2860
P304
P356
10.1158/0008-5472.CAN-07-6822
P407
P577
2008-04-01T00:00:00Z